nodes	percent_of_prediction	percent_of_DWPC	metapath
Mebendazole—CYP1A1—kidney cancer	0.224	0.653	CbGaD
Mebendazole—TUBA1A—Vinblastine—kidney cancer	0.194	0.339	CbGbCtD
Mebendazole—ABCB1—kidney cancer	0.119	0.347	CbGaD
Mebendazole—TUBB4B—Paclitaxel—kidney cancer	0.0844	0.147	CbGbCtD
Mebendazole—TUBB4B—Vinblastine—kidney cancer	0.074	0.129	CbGbCtD
Mebendazole—TUBB4B—Vincristine—kidney cancer	0.0728	0.127	CbGbCtD
Mebendazole—ABCB1—Temsirolimus—kidney cancer	0.0175	0.0306	CbGbCtD
Mebendazole—CYP1A1—Erlotinib—kidney cancer	0.0168	0.0293	CbGbCtD
Mebendazole—CYP3A4—Everolimus—kidney cancer	0.0155	0.0271	CbGbCtD
Mebendazole—CYP3A4—Temsirolimus—kidney cancer	0.0105	0.0183	CbGbCtD
Mebendazole—ABCB1—Pazopanib—kidney cancer	0.0092	0.0161	CbGbCtD
Mebendazole—ABCB1—Dactinomycin—kidney cancer	0.00841	0.0147	CbGbCtD
Mebendazole—ABCB1—Gemcitabine—kidney cancer	0.00665	0.0116	CbGbCtD
Mebendazole—ABCB1—Erlotinib—kidney cancer	0.00656	0.0115	CbGbCtD
Mebendazole—ABCB1—Paclitaxel—kidney cancer	0.00601	0.0105	CbGbCtD
Mebendazole—CYP3A4—Pazopanib—kidney cancer	0.00551	0.00962	CbGbCtD
Mebendazole—ABCB1—Sorafenib—kidney cancer	0.00534	0.00932	CbGbCtD
Mebendazole—ABCB1—Vinblastine—kidney cancer	0.00527	0.0092	CbGbCtD
Mebendazole—ABCB1—Vincristine—kidney cancer	0.00518	0.00905	CbGbCtD
Mebendazole—ABCB1—Sunitinib—kidney cancer	0.00432	0.00755	CbGbCtD
Mebendazole—CYP3A4—Erlotinib—kidney cancer	0.00393	0.00687	CbGbCtD
Mebendazole—Prolonged menses—Vincristine—kidney cancer	0.00386	0.1	CcSEcCtD
Mebendazole—CYP3A4—Paclitaxel—kidney cancer	0.0036	0.00629	CbGbCtD
Mebendazole—ABCB1—Doxorubicin—kidney cancer	0.00324	0.00565	CbGbCtD
Mebendazole—CYP3A4—Sorafenib—kidney cancer	0.0032	0.00558	CbGbCtD
Mebendazole—CYP3A4—Vinblastine—kidney cancer	0.00316	0.00551	CbGbCtD
Mebendazole—CYP3A4—Vincristine—kidney cancer	0.0031	0.00542	CbGbCtD
Mebendazole—CYP3A4—Sunitinib—kidney cancer	0.00259	0.00452	CbGbCtD
Mebendazole—TUBA1A—Zalcitabine—Gemcitabine—kidney cancer	0.00226	0.826	CbGdCrCtD
Mebendazole—Menorrhagia—Pazopanib—kidney cancer	0.00196	0.0508	CcSEcCtD
Mebendazole—CYP3A4—Doxorubicin—kidney cancer	0.00194	0.00339	CbGbCtD
Mebendazole—CYP3A4—urine—kidney cancer	0.00165	0.0839	CbGeAlD
Mebendazole—TUBA1A—nephron tubule—kidney cancer	0.00162	0.0825	CbGeAlD
Mebendazole—Menorrhagia—Everolimus—kidney cancer	0.00155	0.0401	CcSEcCtD
Mebendazole—TUBA1A—renal system—kidney cancer	0.00148	0.075	CbGeAlD
Mebendazole—TUBA1A—kidney—kidney cancer	0.00143	0.0725	CbGeAlD
Mebendazole—TUBA1A—cortex of kidney—kidney cancer	0.00139	0.0706	CbGeAlD
Mebendazole—TUBA1A—gonad—kidney cancer	0.00132	0.0672	CbGeAlD
Mebendazole—TUBA1A—cardiac atrium—kidney cancer	0.00132	0.0671	CbGeAlD
Mebendazole—Menorrhagia—Vincristine—kidney cancer	0.00109	0.0283	CcSEcCtD
Mebendazole—TUBB4B—nephron tubule—kidney cancer	0.00108	0.055	CbGeAlD
Mebendazole—TUBB4B—renal system—kidney cancer	0.000984	0.05	CbGeAlD
Mebendazole—TUBB4B—kidney—kidney cancer	0.000951	0.0483	CbGeAlD
Mebendazole—TUBB4B—cortex of kidney—kidney cancer	0.000927	0.047	CbGeAlD
Mebendazole—Neutropenia—Temsirolimus—kidney cancer	0.000904	0.0234	CcSEcCtD
Mebendazole—TUBB4B—gonad—kidney cancer	0.000883	0.0448	CbGeAlD
Mebendazole—TUBB4B—cardiac atrium—kidney cancer	0.000881	0.0447	CbGeAlD
Mebendazole—Neutropenia—Pazopanib—kidney cancer	0.000851	0.0221	CcSEcCtD
Mebendazole—Albendazole—CYP1A1—kidney cancer	0.000712	0.211	CrCbGaD
Mebendazole—Neutropenia—Everolimus—kidney cancer	0.000672	0.0174	CcSEcCtD
Mebendazole—Neutropenia—Erlotinib—kidney cancer	0.000649	0.0168	CcSEcCtD
Mebendazole—Angioedema—Temsirolimus—kidney cancer	0.000615	0.0159	CcSEcCtD
Mebendazole—Agranulocytosis—Vinblastine—kidney cancer	0.000601	0.0156	CcSEcCtD
Mebendazole—Neutropenia—Sorafenib—kidney cancer	0.000584	0.0151	CcSEcCtD
Mebendazole—Convulsion—Temsirolimus—kidney cancer	0.000583	0.0151	CcSEcCtD
Mebendazole—Hepatitis—Everolimus—kidney cancer	0.000575	0.0149	CcSEcCtD
Mebendazole—Neutropenia—Sunitinib—kidney cancer	0.000562	0.0145	CcSEcCtD
Mebendazole—Hepatitis—Erlotinib—kidney cancer	0.000555	0.0144	CcSEcCtD
Mebendazole—CYP1A1—renal system—kidney cancer	0.000551	0.028	CbGeAlD
Mebendazole—CYP1A1—kidney—kidney cancer	0.000533	0.027	CbGeAlD
Mebendazole—Neutropenia—Dactinomycin—kidney cancer	0.000532	0.0138	CcSEcCtD
Mebendazole—Ketorolac—PTGS1—kidney cancer	0.000501	0.148	CrCbGaD
Mebendazole—CYP1A1—cardiac atrium—kidney cancer	0.000494	0.0251	CbGeAlD
Mebendazole—Hepatitis—Sunitinib—kidney cancer	0.000481	0.0124	CcSEcCtD
Mebendazole—TUBA1A—Azacitidine—Gemcitabine—kidney cancer	0.000475	0.174	CbGdCrCtD
Mebendazole—Neutropenia—Vincristine—kidney cancer	0.000475	0.0123	CcSEcCtD
Mebendazole—Agranulocytosis—Dactinomycin—kidney cancer	0.000473	0.0123	CcSEcCtD
Mebendazole—Angioedema—Everolimus—kidney cancer	0.000458	0.0119	CcSEcCtD
Mebendazole—Hepatitis—Dactinomycin—kidney cancer	0.000455	0.0118	CcSEcCtD
Mebendazole—Neutropenia—Gemcitabine—kidney cancer	0.000451	0.0117	CcSEcCtD
Mebendazole—Gastrointestinal pain—Temsirolimus—kidney cancer	0.000449	0.0116	CcSEcCtD
Mebendazole—Convulsion—Vinblastine—kidney cancer	0.000436	0.0113	CcSEcCtD
Mebendazole—Abdominal pain—Temsirolimus—kidney cancer	0.000434	0.0113	CcSEcCtD
Mebendazole—Convulsion—Everolimus—kidney cancer	0.000434	0.0112	CcSEcCtD
Mebendazole—Gastrointestinal pain—Pazopanib—kidney cancer	0.000423	0.011	CcSEcCtD
Mebendazole—Abdominal pain—Pazopanib—kidney cancer	0.000409	0.0106	CcSEcCtD
Mebendazole—Tiaprofenic acid—PTGS1—kidney cancer	0.000409	0.121	CrCbGaD
Mebendazole—Hypersensitivity—Temsirolimus—kidney cancer	0.000405	0.0105	CcSEcCtD
Mebendazole—CYP3A4—renal system—kidney cancer	0.000404	0.0205	CbGeAlD
Mebendazole—Agranulocytosis—Gemcitabine—kidney cancer	0.000401	0.0104	CcSEcCtD
Mebendazole—Angioedema—Sorafenib—kidney cancer	0.000397	0.0103	CcSEcCtD
Mebendazole—CYP3A4—kidney—kidney cancer	0.000391	0.0198	CbGeAlD
Mebendazole—Nepafenac—PTGS1—kidney cancer	0.000389	0.115	CrCbGaD
Mebendazole—Angioedema—Sunitinib—kidney cancer	0.000382	0.0099	CcSEcCtD
Mebendazole—Albendazole—ABCB1—kidney cancer	0.000378	0.112	CrCbGaD
Mebendazole—Neutropenia—Paclitaxel—kidney cancer	0.000377	0.00977	CcSEcCtD
Mebendazole—Convulsion—Sunitinib—kidney cancer	0.000363	0.00939	CcSEcCtD
Mebendazole—Rash—Temsirolimus—kidney cancer	0.000347	0.00897	CcSEcCtD
Mebendazole—Dermatitis—Temsirolimus—kidney cancer	0.000346	0.00897	CcSEcCtD
Mebendazole—Gastrointestinal pain—Vinblastine—kidney cancer	0.000336	0.00869	CcSEcCtD
Mebendazole—Gastrointestinal pain—Everolimus—kidney cancer	0.000334	0.00866	CcSEcCtD
Mebendazole—Rash—Pazopanib—kidney cancer	0.000326	0.00846	CcSEcCtD
Mebendazole—Dermatitis—Pazopanib—kidney cancer	0.000326	0.00845	CcSEcCtD
Mebendazole—Abdominal pain—Vinblastine—kidney cancer	0.000324	0.0084	CcSEcCtD
Mebendazole—Abdominal pain—Everolimus—kidney cancer	0.000323	0.00837	CcSEcCtD
Mebendazole—Gastrointestinal pain—Erlotinib—kidney cancer	0.000323	0.00835	CcSEcCtD
Mebendazole—ABCB1—nephron tubule—kidney cancer	0.000315	0.016	CbGeAlD
Mebendazole—Abdominal pain—Erlotinib—kidney cancer	0.000312	0.00808	CcSEcCtD
Mebendazole—Neutropenia—Capecitabine—kidney cancer	0.00031	0.00802	CcSEcCtD
Mebendazole—Convulsion—Vincristine—kidney cancer	0.000307	0.00794	CcSEcCtD
Mebendazole—Hypersensitivity—Vinblastine—kidney cancer	0.000302	0.00783	CcSEcCtD
Mebendazole—Hypersensitivity—Everolimus—kidney cancer	0.000301	0.0078	CcSEcCtD
Mebendazole—Gastrointestinal pain—Sorafenib—kidney cancer	0.00029	0.00752	CcSEcCtD
Mebendazole—Ketorolac—PTGS2—kidney cancer	0.000287	0.0848	CrCbGaD
Mebendazole—ABCB1—renal system—kidney cancer	0.000286	0.0145	CbGeAlD
Mebendazole—Urticaria—Sorafenib—kidney cancer	0.000282	0.0073	CcSEcCtD
Mebendazole—Abdominal pain—Sorafenib—kidney cancer	0.000281	0.00727	CcSEcCtD
Mebendazole—Gastrointestinal pain—Sunitinib—kidney cancer	0.000279	0.00723	CcSEcCtD
Mebendazole—ABCB1—kidney—kidney cancer	0.000277	0.014	CbGeAlD
Mebendazole—Agranulocytosis—Capecitabine—kidney cancer	0.000275	0.00713	CcSEcCtD
Mebendazole—Abdominal pain—Sunitinib—kidney cancer	0.00027	0.00699	CcSEcCtD
Mebendazole—ABCB1—cortex of kidney—kidney cancer	0.00027	0.0137	CbGeAlD
Mebendazole—Hepatitis—Capecitabine—kidney cancer	0.000265	0.00686	CcSEcCtD
Mebendazole—Gastrointestinal pain—Dactinomycin—kidney cancer	0.000264	0.00685	CcSEcCtD
Mebendazole—Hypersensitivity—Sorafenib—kidney cancer	0.000261	0.00677	CcSEcCtD
Mebendazole—Rash—Everolimus—kidney cancer	0.000258	0.00668	CcSEcCtD
Mebendazole—Dermatitis—Everolimus—kidney cancer	0.000258	0.00667	CcSEcCtD
Mebendazole—Angioedema—Paclitaxel—kidney cancer	0.000257	0.00665	CcSEcCtD
Mebendazole—ABCB1—gonad—kidney cancer	0.000257	0.013	CbGeAlD
Mebendazole—Abdominal pain—Dactinomycin—kidney cancer	0.000256	0.00662	CcSEcCtD
Mebendazole—Hypersensitivity—Sunitinib—kidney cancer	0.000252	0.00652	CcSEcCtD
Mebendazole—Rash—Erlotinib—kidney cancer	0.000249	0.00644	CcSEcCtD
Mebendazole—Dermatitis—Erlotinib—kidney cancer	0.000248	0.00644	CcSEcCtD
Mebendazole—Convulsion—Paclitaxel—kidney cancer	0.000244	0.00631	CcSEcCtD
Mebendazole—Hypersensitivity—Dactinomycin—kidney cancer	0.000238	0.00617	CcSEcCtD
Mebendazole—Gastrointestinal pain—Vincristine—kidney cancer	0.000236	0.00612	CcSEcCtD
Mebendazole—Tiaprofenic acid—PTGS2—kidney cancer	0.000234	0.0692	CrCbGaD
Mebendazole—Abdominal pain—Vincristine—kidney cancer	0.000228	0.00591	CcSEcCtD
Mebendazole—Rash—Sorafenib—kidney cancer	0.000224	0.0058	CcSEcCtD
Mebendazole—Dermatitis—Sorafenib—kidney cancer	0.000224	0.00579	CcSEcCtD
Mebendazole—Nepafenac—PTGS2—kidney cancer	0.000222	0.0658	CrCbGaD
Mebendazole—Rash—Sunitinib—kidney cancer	0.000215	0.00558	CcSEcCtD
Mebendazole—Dermatitis—Sunitinib—kidney cancer	0.000215	0.00557	CcSEcCtD
Mebendazole—Hypersensitivity—Vincristine—kidney cancer	0.000213	0.00551	CcSEcCtD
Mebendazole—Rash—Dactinomycin—kidney cancer	0.000204	0.00528	CcSEcCtD
Mebendazole—Neutropenia—Doxorubicin—kidney cancer	0.0002	0.00517	CcSEcCtD
Mebendazole—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000188	0.00486	CcSEcCtD
Mebendazole—Urticaria—Paclitaxel—kidney cancer	0.000182	0.00472	CcSEcCtD
Mebendazole—Rash—Vincristine—kidney cancer	0.000182	0.00472	CcSEcCtD
Mebendazole—Dermatitis—Vincristine—kidney cancer	0.000182	0.00471	CcSEcCtD
Mebendazole—Abdominal pain—Paclitaxel—kidney cancer	0.000181	0.0047	CcSEcCtD
Mebendazole—Agranulocytosis—Doxorubicin—kidney cancer	0.000178	0.0046	CcSEcCtD
Mebendazole—Rash—Gemcitabine—kidney cancer	0.000173	0.00447	CcSEcCtD
Mebendazole—Dermatitis—Gemcitabine—kidney cancer	0.000173	0.00447	CcSEcCtD
Mebendazole—Hepatitis—Doxorubicin—kidney cancer	0.000171	0.00442	CcSEcCtD
Mebendazole—Hypersensitivity—Paclitaxel—kidney cancer	0.000169	0.00438	CcSEcCtD
Mebendazole—Ketoprofen—PTGS1—kidney cancer	0.000158	0.0466	CrCbGaD
Mebendazole—Gastrointestinal pain—Capecitabine—kidney cancer	0.000154	0.00399	CcSEcCtD
Mebendazole—Urticaria—Capecitabine—kidney cancer	0.00015	0.00387	CcSEcCtD
Mebendazole—Abdominal pain—Capecitabine—kidney cancer	0.000149	0.00385	CcSEcCtD
Mebendazole—Rash—Paclitaxel—kidney cancer	0.000145	0.00375	CcSEcCtD
Mebendazole—Dermatitis—Paclitaxel—kidney cancer	0.000145	0.00374	CcSEcCtD
Mebendazole—Hypersensitivity—Capecitabine—kidney cancer	0.000139	0.00359	CcSEcCtD
Mebendazole—Convulsion—Doxorubicin—kidney cancer	0.000129	0.00334	CcSEcCtD
Mebendazole—Rash—Capecitabine—kidney cancer	0.000119	0.00307	CcSEcCtD
Mebendazole—Dermatitis—Capecitabine—kidney cancer	0.000119	0.00307	CcSEcCtD
Mebendazole—Gastrointestinal pain—Doxorubicin—kidney cancer	9.92e-05	0.00257	CcSEcCtD
Mebendazole—Urticaria—Doxorubicin—kidney cancer	9.64e-05	0.0025	CcSEcCtD
Mebendazole—Abdominal pain—Doxorubicin—kidney cancer	9.59e-05	0.00248	CcSEcCtD
Mebendazole—Ketoprofen—PTGS2—kidney cancer	9.01e-05	0.0267	CrCbGaD
Mebendazole—Hypersensitivity—Doxorubicin—kidney cancer	8.94e-05	0.00232	CcSEcCtD
Mebendazole—Rash—Doxorubicin—kidney cancer	7.65e-05	0.00198	CcSEcCtD
Mebendazole—Dermatitis—Doxorubicin—kidney cancer	7.64e-05	0.00198	CcSEcCtD
Mebendazole—TUBA1A—Metabolism of proteins—BCHE—kidney cancer	5.68e-05	0.00289	CbGpPWpGaD
Mebendazole—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—kidney cancer	5.6e-05	0.00285	CbGpPWpGaD
Mebendazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—kidney cancer	5.34e-05	0.00272	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle—BRCA2—kidney cancer	5.3e-05	0.0027	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle—CDKN2B—kidney cancer	5.26e-05	0.00268	CbGpPWpGaD
Mebendazole—TUBB4B—Metabolism of proteins—MME—kidney cancer	5.14e-05	0.00262	CbGpPWpGaD
Mebendazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CRABP1—kidney cancer	5.14e-05	0.00262	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle, Mitotic—BIRC5—kidney cancer	5.07e-05	0.00258	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle, Mitotic—PSMD7—kidney cancer	4.86e-05	0.00247	CbGpPWpGaD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor—RAF1—kidney cancer	4.82e-05	0.00245	CbGpPWpGaD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor—RELA—kidney cancer	4.8e-05	0.00244	CbGpPWpGaD
Mebendazole—TUBB4B—Metabolism of proteins—HSPD1—kidney cancer	4.78e-05	0.00243	CbGpPWpGaD
Mebendazole—TUBB4B—Metabolism of proteins—RPL14—kidney cancer	4.78e-05	0.00243	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle, Mitotic—AURKA—kidney cancer	4.73e-05	0.00241	CbGpPWpGaD
Mebendazole—CYP1A1—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	4.72e-05	0.00241	CbGpPWpGaD
Mebendazole—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—kidney cancer	4.66e-05	0.00237	CbGpPWpGaD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—kidney cancer	4.66e-05	0.00237	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle—BIRC5—kidney cancer	4.54e-05	0.00231	CbGpPWpGaD
Mebendazole—CYP1A1—Biological oxidations—GSTT1—kidney cancer	4.52e-05	0.0023	CbGpPWpGaD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—CDKN1B—kidney cancer	4.41e-05	0.00225	CbGpPWpGaD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor—CDKN1B—kidney cancer	4.41e-05	0.00225	CbGpPWpGaD
Mebendazole—TUBA1A—Metabolism of proteins—IGF2—kidney cancer	4.4e-05	0.00224	CbGpPWpGaD
Mebendazole—CYP1A1—Arachidonic acid metabolism—PTGS2—kidney cancer	4.36e-05	0.00222	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—PSMD7—kidney cancer	4.34e-05	0.00221	CbGpPWpGaD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—kidney cancer	4.32e-05	0.0022	CbGpPWpGaD
Mebendazole—CYP1A1—Biological oxidations—PTGS1—kidney cancer	4.23e-05	0.00216	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—AURKA—kidney cancer	4.23e-05	0.00215	CbGpPWpGaD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—kidney cancer	4.2e-05	0.00214	CbGpPWpGaD
Mebendazole—ABCB1—HIF-1-alpha transcription factor network—HIF1A—kidney cancer	4.17e-05	0.00212	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—JUND—kidney cancer	4.02e-05	0.00205	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—APAF1—kidney cancer	4.02e-05	0.00205	CbGpPWpGaD
Mebendazole—TUBB4B—Metabolism of proteins—ACHE—kidney cancer	3.94e-05	0.00201	CbGpPWpGaD
Mebendazole—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	3.92e-05	0.002	CbGpPWpGaD
Mebendazole—TUBB4B—Metabolism of proteins—EIF4EBP1—kidney cancer	3.89e-05	0.00198	CbGpPWpGaD
Mebendazole—CYP3A4—Tryptophan metabolism—CYP1A1—kidney cancer	3.86e-05	0.00196	CbGpPWpGaD
Mebendazole—CYP1A1—Phase 1 - Functionalization of compounds—POMC—kidney cancer	3.83e-05	0.00195	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—kidney cancer	3.81e-05	0.00194	CbGpPWpGaD
Mebendazole—CYP3A4—Biological oxidations—ALDH1A1—kidney cancer	3.78e-05	0.00193	CbGpPWpGaD
Mebendazole—TUBB4B—Metabolism of proteins—PAX6—kidney cancer	3.75e-05	0.00191	CbGpPWpGaD
Mebendazole—ABCB1—Transmembrane transport of small molecules—RYR1—kidney cancer	3.74e-05	0.00191	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	3.73e-05	0.0019	CbGpPWpGaD
Mebendazole—TUBB4B—Transmembrane transport of small molecules—SLC5A5—kidney cancer	3.73e-05	0.0019	CbGpPWpGaD
Mebendazole—TUBB4B—Metabolism of proteins—CTSD—kidney cancer	3.73e-05	0.0019	CbGpPWpGaD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—kidney cancer	3.67e-05	0.00187	CbGpPWpGaD
Mebendazole—TUBB4B—Transmembrane transport of small molecules—SLC2A1—kidney cancer	3.6e-05	0.00183	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle, Mitotic—CDKN2B—kidney cancer	3.55e-05	0.00181	CbGpPWpGaD
Mebendazole—TUBB4B—Metabolism of proteins—BCHE—kidney cancer	3.43e-05	0.00175	CbGpPWpGaD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor—MYC—kidney cancer	3.38e-05	0.00172	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle, Mitotic—CDKN2A—kidney cancer	3.36e-05	0.00171	CbGpPWpGaD
Mebendazole—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—kidney cancer	3.35e-05	0.00171	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—ACHE—kidney cancer	3.32e-05	0.00169	CbGpPWpGaD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor—MAPK1—kidney cancer	3.3e-05	0.00168	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—BRCA2—kidney cancer	3.2e-05	0.00163	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—CDKN2B—kidney cancer	3.17e-05	0.00162	CbGpPWpGaD
Mebendazole—CYP1A1—Biological oxidations—GSTP1—kidney cancer	3.13e-05	0.00159	CbGpPWpGaD
Mebendazole—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—kidney cancer	3.12e-05	0.00159	CbGpPWpGaD
Mebendazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	3.12e-05	0.00159	CbGpPWpGaD
Mebendazole—CYP1A1—Metapathway biotransformation—GSTP1—kidney cancer	3.09e-05	0.00157	CbGpPWpGaD
Mebendazole—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	3.08e-05	0.00157	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle, Mitotic—BIRC5—kidney cancer	3.06e-05	0.00156	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—ANXA1—kidney cancer	3.05e-05	0.00155	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle—CDKN2A—kidney cancer	3.01e-05	0.00153	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle, Mitotic—CDKN1B—kidney cancer	2.98e-05	0.00152	CbGpPWpGaD
Mebendazole—TUBA1A—Metabolism of proteins—POMC—kidney cancer	2.94e-05	0.0015	CbGpPWpGaD
Mebendazole—CYP1A1—Biological oxidations—GSTM1—kidney cancer	2.88e-05	0.00147	CbGpPWpGaD
Mebendazole—TUBB4B—Transmembrane transport of small molecules—ABCB1—kidney cancer	2.84e-05	0.00145	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle, Mitotic—CCND1—kidney cancer	2.84e-05	0.00145	CbGpPWpGaD
Mebendazole—CYP1A1—Metapathway biotransformation—GSTM1—kidney cancer	2.84e-05	0.00145	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—BIRC5—kidney cancer	2.74e-05	0.00139	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—JUNB—kidney cancer	2.74e-05	0.00139	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—PAK1—kidney cancer	2.74e-05	0.00139	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle—CDKN1B—kidney cancer	2.66e-05	0.00136	CbGpPWpGaD
Mebendazole—TUBB4B—Metabolism of proteins—IGF2—kidney cancer	2.66e-05	0.00135	CbGpPWpGaD
Mebendazole—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—kidney cancer	2.56e-05	0.00131	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—EGR1—kidney cancer	2.56e-05	0.0013	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle—CCND1—kidney cancer	2.54e-05	0.00129	CbGpPWpGaD
Mebendazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	2.53e-05	0.00129	CbGpPWpGaD
Mebendazole—ABCB1—HIF-1-alpha transcription factor network—JUN—kidney cancer	2.51e-05	0.00128	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—ACY1—kidney cancer	2.4e-05	0.00122	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle, Mitotic—MAPK3—kidney cancer	2.34e-05	0.00119	CbGpPWpGaD
Mebendazole—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	2.32e-05	0.00118	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle, Mitotic—MYC—kidney cancer	2.28e-05	0.00116	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—kidney cancer	2.25e-05	0.00114	CbGpPWpGaD
Mebendazole—ABCB1—Allograft Rejection—IL2—kidney cancer	2.24e-05	0.00114	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle, Mitotic—MAPK1—kidney cancer	2.23e-05	0.00114	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—kidney cancer	2.23e-05	0.00113	CbGpPWpGaD
Mebendazole—CYP3A4—Biological oxidations—GSTT1—kidney cancer	2.22e-05	0.00113	CbGpPWpGaD
Mebendazole—ABCB1—HIF-1-alpha transcription factor network—VEGFA—kidney cancer	2.2e-05	0.00112	CbGpPWpGaD
Mebendazole—ABCB1—Transmembrane transport of small molecules—ATP7B—kidney cancer	2.15e-05	0.00109	CbGpPWpGaD
Mebendazole—ABCB1—Transmembrane transport of small molecules—ANXA2—kidney cancer	2.15e-05	0.00109	CbGpPWpGaD
Mebendazole—ABCB1—Transmembrane transport of small molecules—SLC5A3—kidney cancer	2.15e-05	0.00109	CbGpPWpGaD
Mebendazole—TUBA1A—Metabolism of proteins—CTNNB1—kidney cancer	2.1e-05	0.00107	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle—MAPK3—kidney cancer	2.09e-05	0.00107	CbGpPWpGaD
Mebendazole—CYP3A4—Biological oxidations—PTGS1—kidney cancer	2.08e-05	0.00106	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	2.05e-05	0.00104	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—PDHB—kidney cancer	2.04e-05	0.00104	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle—MYC—kidney cancer	2.04e-05	0.00104	CbGpPWpGaD
Mebendazole—CYP1A1—Biological oxidations—POMC—kidney cancer	2.03e-05	0.00104	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle, Mitotic—CDKN2A—kidney cancer	2.03e-05	0.00103	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle—MAPK1—kidney cancer	1.99e-05	0.00101	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—CCBL1—kidney cancer	1.92e-05	0.000977	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—ACY1—kidney cancer	1.92e-05	0.000976	CbGpPWpGaD
Mebendazole—ABCB1—Allograft Rejection—VEGFA—kidney cancer	1.9e-05	0.000969	CbGpPWpGaD
Mebendazole—CYP3A4—Phase 1 - Functionalization of compounds—POMC—kidney cancer	1.88e-05	0.00096	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—CDKN2A—kidney cancer	1.82e-05	0.000924	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle, Mitotic—CDKN1B—kidney cancer	1.8e-05	0.000916	CbGpPWpGaD
Mebendazole—TUBB4B—Metabolism of proteins—POMC—kidney cancer	1.77e-05	0.000903	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	1.73e-05	0.000883	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle, Mitotic—CCND1—kidney cancer	1.72e-05	0.000873	CbGpPWpGaD
Mebendazole—TUBA1A—Cell Cycle—TP53—kidney cancer	1.67e-05	0.000852	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—PPAT—kidney cancer	1.66e-05	0.000847	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—GLIPR1—kidney cancer	1.66e-05	0.000847	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	1.64e-05	0.000836	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—PDHB—kidney cancer	1.63e-05	0.00083	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	1.63e-05	0.000828	CbGpPWpGaD
Mebendazole—TUBB4B—Transmembrane transport of small molecules—RAF1—kidney cancer	1.61e-05	0.00082	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—CDKN1B—kidney cancer	1.61e-05	0.000819	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—APC—kidney cancer	1.57e-05	0.000799	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—APRT—kidney cancer	1.55e-05	0.000787	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—FH—kidney cancer	1.55e-05	0.000787	CbGpPWpGaD
Mebendazole—CYP3A4—Biological oxidations—GSTP1—kidney cancer	1.54e-05	0.000785	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—CCND1—kidney cancer	1.53e-05	0.000781	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—CCBL1—kidney cancer	1.53e-05	0.00078	CbGpPWpGaD
Mebendazole—CYP3A4—Metapathway biotransformation—GSTP1—kidney cancer	1.52e-05	0.000774	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	1.51e-05	0.00077	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—GPC3—kidney cancer	1.45e-05	0.00074	CbGpPWpGaD
Mebendazole—CYP3A4—Biological oxidations—GSTM1—kidney cancer	1.42e-05	0.000721	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle, Mitotic—MAPK3—kidney cancer	1.41e-05	0.00072	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—CA2—kidney cancer	1.41e-05	0.00072	CbGpPWpGaD
Mebendazole—CYP3A4—Metapathway biotransformation—GSTM1—kidney cancer	1.4e-05	0.000711	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—ALAD—kidney cancer	1.38e-05	0.000702	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle, Mitotic—MYC—kidney cancer	1.38e-05	0.000701	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle, Mitotic—MAPK1—kidney cancer	1.35e-05	0.000685	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—ST3GAL2—kidney cancer	1.35e-05	0.000685	CbGpPWpGaD
Mebendazole—CYP3A4—Biological oxidations—CYP1A1—kidney cancer	1.34e-05	0.000684	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—GLIPR1—kidney cancer	1.33e-05	0.000677	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—PPAT—kidney cancer	1.33e-05	0.000677	CbGpPWpGaD
Mebendazole—CYP3A4—Metapathway biotransformation—CYP1A1—kidney cancer	1.32e-05	0.000674	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—ALDH1A1—kidney cancer	1.31e-05	0.00067	CbGpPWpGaD
Mebendazole—TUBB4B—Metabolism of proteins—CTNNB1—kidney cancer	1.27e-05	0.000645	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—MAPK3—kidney cancer	1.26e-05	0.000644	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—SLC5A3—kidney cancer	1.26e-05	0.000642	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—PGK1—kidney cancer	1.26e-05	0.000642	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—LDHB—kidney cancer	1.24e-05	0.000629	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—FH—kidney cancer	1.23e-05	0.000629	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—APRT—kidney cancer	1.23e-05	0.000629	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—kidney cancer	1.23e-05	0.000627	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—MYC—kidney cancer	1.23e-05	0.000626	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—kidney cancer	1.22e-05	0.000621	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—MAPK1—kidney cancer	1.2e-05	0.000613	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—kidney cancer	1.19e-05	0.000607	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—ACY1—kidney cancer	1.18e-05	0.000601	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—GPC3—kidney cancer	1.16e-05	0.000591	CbGpPWpGaD
Mebendazole—ABCB1—Transmembrane transport of small molecules—SLC5A5—kidney cancer	1.13e-05	0.000577	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—CA2—kidney cancer	1.13e-05	0.000575	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—kidney cancer	1.13e-05	0.000575	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—ALAD—kidney cancer	1.1e-05	0.000561	CbGpPWpGaD
Mebendazole—ABCB1—Transmembrane transport of small molecules—SLC2A1—kidney cancer	1.09e-05	0.000558	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—kidney cancer	1.08e-05	0.000548	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—ST3GAL2—kidney cancer	1.07e-05	0.000547	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—kidney cancer	1.07e-05	0.000547	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—CA9—kidney cancer	1.07e-05	0.000546	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—kidney cancer	1.07e-05	0.000543	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—ALDH1A1—kidney cancer	1.05e-05	0.000535	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—kidney cancer	1.04e-05	0.000529	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—TP53—kidney cancer	1.01e-05	0.000514	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—SLC5A3—kidney cancer	1.01e-05	0.000513	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—PGK1—kidney cancer	1.01e-05	0.000513	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—PDHB—kidney cancer	1e-05	0.000511	CbGpPWpGaD
Mebendazole—CYP3A4—Biological oxidations—POMC—kidney cancer	1e-05	0.00051	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—LDHB—kidney cancer	9.87e-06	0.000503	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—CCBL1—kidney cancer	9.44e-06	0.000481	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	9.39e-06	0.000478	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—CRABP1—kidney cancer	9.11e-06	0.000464	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	8.88e-06	0.000452	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	8.64e-06	0.00044	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—CA9—kidney cancer	8.56e-06	0.000436	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—ITPR2—kidney cancer	8.47e-06	0.000431	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	8.45e-06	0.00043	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—PPAT—kidney cancer	8.18e-06	0.000417	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—GLIPR1—kidney cancer	8.18e-06	0.000417	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	7.98e-06	0.000406	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—POMC—kidney cancer	7.81e-06	0.000398	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—GSTT1—kidney cancer	7.73e-06	0.000393	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—ACHE—kidney cancer	7.73e-06	0.000393	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—FH—kidney cancer	7.61e-06	0.000387	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—APRT—kidney cancer	7.61e-06	0.000387	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	7.33e-06	0.000373	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—SCARB1—kidney cancer	7.31e-06	0.000372	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—CRABP1—kidney cancer	7.28e-06	0.000371	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—PTGS1—kidney cancer	7.24e-06	0.000369	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—GPC3—kidney cancer	7.15e-06	0.000364	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—PSMD7—kidney cancer	7.1e-06	0.000362	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	7.09e-06	0.000361	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—CA2—kidney cancer	6.96e-06	0.000354	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—ALAD—kidney cancer	6.78e-06	0.000345	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—ITPR2—kidney cancer	6.77e-06	0.000345	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—BCHE—kidney cancer	6.73e-06	0.000343	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—SLC5A5—kidney cancer	6.65e-06	0.000339	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—ST3GAL2—kidney cancer	6.62e-06	0.000337	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—ALDH1A1—kidney cancer	6.47e-06	0.000329	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—SLC2A1—kidney cancer	6.42e-06	0.000327	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	6.23e-06	0.000317	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—PGK1—kidney cancer	6.2e-06	0.000316	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—SLC5A3—kidney cancer	6.2e-06	0.000316	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—ACHE—kidney cancer	6.17e-06	0.000314	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—GSTT1—kidney cancer	6.17e-06	0.000314	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—LDHB—kidney cancer	6.08e-06	0.00031	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—SCARB1—kidney cancer	5.84e-06	0.000297	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—PTGS1—kidney cancer	5.78e-06	0.000294	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—PSMD7—kidney cancer	5.67e-06	0.000289	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	5.43e-06	0.000277	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—BCHE—kidney cancer	5.38e-06	0.000274	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—GSTP1—kidney cancer	5.36e-06	0.000273	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—SLC5A5—kidney cancer	5.31e-06	0.00027	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—CA9—kidney cancer	5.27e-06	0.000269	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—SLC2A1—kidney cancer	5.13e-06	0.000261	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—ABCB1—kidney cancer	5.07e-06	0.000258	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—GSTM1—kidney cancer	4.92e-06	0.000251	CbGpPWpGaD
Mebendazole—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	4.89e-06	0.000249	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—CRABP1—kidney cancer	4.48e-06	0.000228	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—GSTP1—kidney cancer	4.28e-06	0.000218	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—ITPR2—kidney cancer	4.17e-06	0.000212	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—GSTM1—kidney cancer	3.93e-06	0.0002	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.83e-06	0.000195	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—ACHE—kidney cancer	3.8e-06	0.000194	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—GSTT1—kidney cancer	3.8e-06	0.000194	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—CYP1A1—kidney cancer	3.73e-06	0.00019	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—SCARB1—kidney cancer	3.6e-06	0.000183	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—PTGS1—kidney cancer	3.56e-06	0.000181	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—PSMD7—kidney cancer	3.49e-06	0.000178	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—POMC—kidney cancer	3.48e-06	0.000177	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—BCHE—kidney cancer	3.31e-06	0.000169	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—SLC5A5—kidney cancer	3.27e-06	0.000167	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—SLC2A1—kidney cancer	3.16e-06	0.000161	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—POMC—kidney cancer	2.78e-06	0.000141	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—PTGS2—kidney cancer	2.77e-06	0.000141	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—GSTP1—kidney cancer	2.64e-06	0.000134	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—ABCB1—kidney cancer	2.49e-06	0.000127	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—GSTM1—kidney cancer	2.42e-06	0.000123	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—PTEN—kidney cancer	2.42e-06	0.000123	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—CYP1A1—kidney cancer	2.3e-06	0.000117	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—PTGS2—kidney cancer	2.22e-06	0.000113	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—PTEN—kidney cancer	1.93e-06	9.84e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—POMC—kidney cancer	1.71e-06	8.72e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—PIK3CA—kidney cancer	1.71e-06	8.69e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—PTGS2—kidney cancer	1.37e-06	6.95e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—PIK3CA—kidney cancer	1.36e-06	6.94e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—PTEN—kidney cancer	1.19e-06	6.06e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—PIK3CA—kidney cancer	8.4e-07	4.28e-05	CbGpPWpGaD
